132 related articles for article (PubMed ID: 9685832)
1. Influence of the phosphate balance on the activity distribution of 99mTc-hydroxy-methylene diphosphonate. Experimental studies in the mouse.
Cronhjort M; Sääf M; Sjöberg HE; Schnell PO; Jacobsson H
Acta Radiol; 1998 Jul; 39(4):427-33. PubMed ID: 9685832
[TBL] [Abstract][Full Text] [Related]
2. Activity in the gastrointestinal tract after administration of bone-seeking radiopharmaceuticals. Experimental studies in mice.
Cronhjort M; Jonsson C; Nilsson SO; Garmelius B; Jacobsson H
Acta Radiol; 1996 Sep; 37(5):785-90. PubMed ID: 8915294
[TBL] [Abstract][Full Text] [Related]
3. Determination of lesion to normal bone uptake ratios of skeletal radiopharmaceuticals by QARG (quantitative autoradiography).
Ghiron J; Volkert WA; Garlich J; Holmes RA
Int J Rad Appl Instrum B; 1991; 18(2):235-40. PubMed ID: 2026500
[TBL] [Abstract][Full Text] [Related]
4. Sympathotropic drugs and the distribution of 99mTc-hydroxymethylene diphosphonate. Experimental studies in the mouse.
Cronhjort M; Jonsson C; Jacobsson H
Acta Radiol; 1999 May; 40(3):309-13. PubMed ID: 10335970
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo studies with pentavalent technetium-99m dimercaptosuccinic acid.
Lam AS; Puncher MR; Blower PJ
Eur J Nucl Med; 1996 Dec; 23(12):1575-82. PubMed ID: 8929310
[TBL] [Abstract][Full Text] [Related]
6. New bone-seeking agent: animal study of Tc-99m-incadronate.
Shigematsu M; Shomi S; Iwao H; Ochi H
Ann Nucl Med; 2002 Feb; 16(1):55-9. PubMed ID: 11922209
[TBL] [Abstract][Full Text] [Related]
7. A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases.
Pauwels EK; Blom J; Camps JA; Hermans J; Rijke AM
Eur J Nucl Med; 1983; 8(3):118-22. PubMed ID: 6220908
[TBL] [Abstract][Full Text] [Related]
8. Short-time ingestion of colas influences the activity distribution at bone scintigraphy: experimental studies in the mouse.
Jacobsson H
J Am Coll Nutr; 2008 Apr; 27(2):332-6. PubMed ID: 18689567
[TBL] [Abstract][Full Text] [Related]
9. Biokinetics of bone tracers by means of deconvolution analysis--comparison of 99mTc MDP, 99mTc DPD and 99mTc EHDP.
Knop J; Stritzke P; Kröger E; Schneider C; Wasmus G
Nuklearmedizin; 1982 Aug; 21(4):145-9. PubMed ID: 6216459
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmacokinetic data for 99mTc-ABP--a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP.
Arteaga de Murphy C; Meléndez-Alafort L; Montoya-Molina CE; Sepúlveda-Méndez J
Nucl Med Biol; 1997 Jan; 24(1):27-33. PubMed ID: 9080472
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of accumulation of 99mTc-MDP to bone: correlation of in vivo data with in vitro data.
Okamoto YM
Radiat Med; 1997; 15(4):209-15. PubMed ID: 9311035
[TBL] [Abstract][Full Text] [Related]
12. A clinical comparison of 99mTc-DPD and two 99mTc-MDP agents.
Vorne M; Vähätalo S; Lantto T
Eur J Nucl Med; 1983; 8(9):395-7. PubMed ID: 6226527
[TBL] [Abstract][Full Text] [Related]
13. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging?
Kumar V; Kumar D; Howman-Giles RB; Little DG
Nucl Med Commun; 2007 Feb; 28(2):101-7. PubMed ID: 17198350
[TBL] [Abstract][Full Text] [Related]
14. Myocardial uptake of bone scintigraphic agents associated with increased pulmonary uptake.
Bach-Gansmo T; Wien TN; Løndalen A; Halvorsen E
Clin Physiol Funct Imaging; 2016 May; 36(3):237-41. PubMed ID: 25524030
[TBL] [Abstract][Full Text] [Related]
15. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate.
Subramanian G; McAfee JG; Thomas FD; Feld TA; Zapf-Longo C; Palladino E
Radiology; 1983 Dec; 149(3):823-8. PubMed ID: 6316414
[TBL] [Abstract][Full Text] [Related]
16. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
[TBL] [Abstract][Full Text] [Related]
17. Localization of 99mTc-diphosphonates in newly formed bone matrix as a measure of bone lesion detectability.
Schuemichen C; Krause T; Umbach G; Wolff T
Nuklearmedizin; 1988 Feb; 27(1):8-11. PubMed ID: 3368337
[TBL] [Abstract][Full Text] [Related]
18. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature.
Ergün EL; Kiratli PO; Günay EC; Erbaş B
Nucl Med Commun; 2006 Nov; 27(11):877-85. PubMed ID: 17021428
[TBL] [Abstract][Full Text] [Related]
19. Increased technetium-99 m hydroxy diphosphonate soft tissue uptake on bone scintigraphy in chronic kidney disease patients with secondary hyperparathyroidism: correlation with hyperphosphataemia.
Enevoldsen LH; Heaf J; Højgaard L; Zerahn B; Hasbak P
Clin Physiol Funct Imaging; 2017 Mar; 37(2):131-136. PubMed ID: 26148143
[TBL] [Abstract][Full Text] [Related]
20. [Quantitative whole-body bone scintigraphy. II. Pharmacokinetics of osteotropic radiopharmaceuticals (author's transl)].
Anger K; Aigner S; Bühler M; Umbach I
Nuklearmedizin; 1980 Jul; 19(3):97-107. PubMed ID: 7465432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
